GW files cannabis-based epilepsy drug in EU and US
After Sativex disappointment, Epidiolex could transform GW’s fortunes.
After Sativex disappointment, Epidiolex could transform GW’s fortunes.
Data also suggests treatment could improve memory
Byteflies’ Sensor Dot will help monitor brain, heart and respiration activity.
But Zynerba’s cannabis epilepsy drug fails in phase 2.
Epidiolex could become a blockbuster if approved in all uses.
Depakine and generics linked with defects including spina bifida.
Votubia gets new indication.
Price of epilepsy drug increased 85,000% since 2001, says FTC.
Takeda makes epilepsy deal as GW prepares for US filing.